Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22234408 | 0.84 | ALDH1A1 (0.46) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL4313351 | 0.84 | EPHX2 (0.44) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL871908 | 0.83 | NPC1 (0.49) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL8347290 | 0.83 | NPC1 (0.49) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL582677 | 0.83 | NPC1 (0.49) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL8352380 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL8353490 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL1588250 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL29224887 | 0.81 | CYP2C19 (0.51) | ALDH1A1CTSLCTSBCTSKAGTR2 | |
| SCHEMBL12017809 | 0.81 | ALDH1A1 (0.49) | ALDH1A1CTSLCTSBCTSKAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743079-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2025015104-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2025015106-A2 | APOL1 INHIBITORS AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-4225435-B1 | AMINOIMIDAZOLE FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20230373930-A1 | AMINOIMIDAZOLE FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373930-A1 | AMINOIMIDAZOLE FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230373930-A1 | AMINOIMIDAZOLE FPR2 AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116390913-A | Aminoimidazole FPR2 agonists | 百时美施贵宝公司 | 2023-07-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | ALDH1A1 1201/4885CTSL 95/4885CTSB 452/4885 |
| US-20230373930-A1 | AMINOIMIDAZOLE FPR2 AGONISTS | FPR2, FPR1, FPR3 | ALDH1A1 3618/4885CTSL 2050/4885CTSB 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.